| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_672f62e7a3a997afc9dc3a228d74ef72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-34 |
| filingDate |
2000-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62d51e7ef1c9a7eb6f0bae3d04d4abd8 |
| publicationDate |
2011-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7939109-B1 |
| titleOfInvention |
Method of treating neoplastic disease in a human or animal patient |
| abstract |
A method of treating neoplastic disease in a human or animal patient is provided comprising administering to the patient an anti-neoplastic effective amount of a composition comprising as the sole pharmaceutically active components (a) copper gluconate or copper orotate; (b) sodium salicylate; (c) vitamin C; (d) manganese gluconate or manganese orotate; and optionally one or more of (e) iron gluconate or iron orotate; (f) sublimed sulphur; and (g) zinc gluconate or zinc orotate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016202346-A1 |
| priorityDate |
1999-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |